ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
39 announcements with these filters
CRISIL Ratings has continued the ratings on Anupam Rasayan India Ltd's bank facilities and non-convertible debentures, maintaining the 'Rating Watch with Developing Implications'.
Promoter Anand Sureshbhai Desai created a pledge on 2,00,000 equity shares of Anupam Rasayan India Limited to secure debt aggregating to ₹160 Crore.
Anupam Rasayan started FY27 with 36% revenue growth, primarily driven by the Jehoshaphat (J-Hock) acquisition and new product commercialization in flow chemistry.
Anupam Rasayan reported strong Q1FY27 consolidated revenue of ₹6,675 Mn, up 36% YoY. Strategy focuses on expanding the fluorination and CDMO platforms via strategic acquisitions of Jayhawk and Bliss GVS Pharma.
Anupam Rasayan India Ltd reported Q1 FY27 revenue of ₹667.5 Crore, a 36% YoY increase. The company signed a ₹2,850 Crore LOI with BASQUEVOLT for specialty chemicals.
Anupam Rasayan India Limited has appointed Mr. Ravi Desai as Chief Operating Officer effective August 14, 2026. He previously served as the company's Sales Head.
Anupam Rasayan India Ltd reported revenue from operations of ₹655 Cr (+34.8% YoY) and net profit of ₹51.2 Cr (+5.6% YoY) for Q1 FY27.
Anupam Rasayan India Limited has allotted equity shares under its Employee Stock Option (ESOP) scheme. This allotment increases the company's total paid-up share capital.
Anupam Rasayan allotted 1,531 equity shares under its ESOP Scheme 2020 to eligible employees. The total exercise realization for this allotment is ₹0.03 Crore.